Kura Oncology (KURA) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Kura Oncology (KURA) over the past year, gaining 62.5% versus a gain of 7.6%. Over five years, PCRX leads with a -31.7% price change compared with -41.2% for KURA. Pacira BioSciences is the larger company by market cap ($1.45 billion vs $943.0 million), about 1.5 times the size, while Kura Oncology is growing revenue faster (+25.2% vs +3.6%).
Pacira BioSciences converts more of its revenue into profit, with a net margin of 1.0% versus -412.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KURA | PCRX |
|---|---|---|
| Share price | $10.60 | $36.31 |
| Market cap | $942.98M | $1.45B |
| 1-day change | +0.76% | -0.22% |
| YTD return | +2.02% | +40.30% |
| 1-year return | +7.61% | +62.46% |
| 5-year return | -41.18% | -31.75% |
| P/E ratio (TTM) | — | 103.74 |
| Forward P/E | — | 10.50 |
| EPS (TTM) | $-3.37 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $67.48M | $726.41M |
| Revenue growth (YoY) | +25.24% | +3.63% |
| Net income (latest FY) | $-278.67M | $7.03M |
| Gross margin | — | 79.39% |
| Operating margin | -449.94% | 2.64% |
| Net margin | -412.95% | 0.97% |
| 52-week high | $13.90 | $36.46 |
| 52-week low | $7.36 | $18.80 |
| Distance from 52-week high | -23.74% | -0.41% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +200.47% | -17.08% |
| Average volume | 1.77M | 1.10M |
| Shares outstanding | 88.96M | 39.91M |
| Employees | 260 | 825 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCRX has outperformed KURA by 54.8 percentage points over the past year.
- Pacira BioSciences is more profitable, keeping 1.0 cents of every revenue dollar as net income versus -412.9 cents for Kura Oncology.
- Kura Oncology grew revenue faster in its latest fiscal year (+25.24% vs +3.63%).
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
KURA vs PCRX FAQ
Which is bigger, Kura Oncology or Pacira BioSciences?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $942.98M for Kura Oncology (KURA).
Which stock has performed better over the past year, KURA or PCRX?
PCRX returned +62.46% over the past 12 months, compared with +7.61% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Kura Oncology and Pacira BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.